Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HITF (Healthcare Industries Task Force): the end of a new beginning for UK medical technology

This article was originally published in Clinica

Executive Summary

It is impossible in a brief summary to do justice to a strategy that seeks to re-steer and energise the £6bn ($11.2bn) machine that is the UK's medical technology industry. But last week's publication of the HITF report is actually just the end of the beginning - the nuts and bolts of a nine-part system designed by around 200 people over the last year to improve the machine's performance. That design is now ready to be engineered into the current R&D, manufacturing, marketing, healthcare delivery and regulatory systems, reports Bernard Murphy

You may also be interested in...



Coronavirus Update: Inovio Begins Phase I Trials of DNA Vaccine, Fast-Track Drug Dialogue Continues

Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?

Switzerland Approves Raft Of Rx-To-OTC Switches

Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.

Who’s Hired? Sandoz Names New Japanese Head

Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.

Topics

UsernamePublicRestriction

Register

MT060270

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel